Brief: Camurus' Oczyesa Receives Marketing Authorization For Treatment Of Acromegaly In The EU
01/07/2025 11:24
July 1 (Reuters) - Camurus AB CAMX.ST: CAMURUS' OCZYESA® RECEIVES MARKETING AUTHORIZATION FOR TREATMENT OF ACROMEGALY IN THE EU Source text: ID:nPnbXTLLCa Further company coverage: CAMX.ST (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat